AR080884A1 - Conjugados de insulina-sirna - Google Patents

Conjugados de insulina-sirna

Info

Publication number
AR080884A1
AR080884A1 ARP110101227A ARP110101227A AR080884A1 AR 080884 A1 AR080884 A1 AR 080884A1 AR P110101227 A ARP110101227 A AR P110101227A AR P110101227 A ARP110101227 A AR P110101227A AR 080884 A1 AR080884 A1 AR 080884A1
Authority
AR
Argentina
Prior art keywords
refers
insulin
specifically
methods
metabolic diseases
Prior art date
Application number
ARP110101227A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR080884A1 publication Critical patent/AR080884A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere de forma general a compuestos terapéuticos y métodos utiles para tratar a enfermedades en seres humanos. Más concretamente, se refiere a métodos y reactivos utiles para tratar a seres humanos que padecen enfermedades metabolicas. Más concretamente, se refiere a conjugados covalentes de insulina y análogos con derivados de ácidos nucleicos que son capaces de modular la expresion de genes. Además, esta se refiere al uso de dichas insulinas conjugadas para el tratamiento de enfermedades metabolicas, incluyendo la diabetes mellitus. Reivindicacion 1: El compuesto quimérico que comprende una insulina y su siRNA.
ARP110101227A 2010-04-14 2011-04-12 Conjugados de insulina-sirna AR080884A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305388 2010-04-14

Publications (1)

Publication Number Publication Date
AR080884A1 true AR080884A1 (es) 2012-05-16

Family

ID=42633135

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101227A AR080884A1 (es) 2010-04-14 2011-04-12 Conjugados de insulina-sirna

Country Status (4)

Country Link
AR (1) AR080884A1 (es)
TW (1) TW201141513A (es)
UY (1) UY33326A (es)
WO (1) WO2011128374A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
MX369511B (es) 2013-04-03 2019-11-11 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2018035380A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE10075034I1 (de) 1987-02-25 2001-05-23 Novo Nordisk As Insulinderivate
RO112873B1 (ro) 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US20060019913A1 (en) 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
AU2003283951A1 (en) 2002-05-23 2004-03-03 Ceptyr, Inc. Modulation of biological signal transduction by rna interference
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
JP5624256B2 (ja) * 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20060040882A1 (en) 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
JP4818361B2 (ja) 2005-07-08 2011-11-16 バイオコン・リミテッド インスリン複合体の調製
US8058391B2 (en) 2005-10-13 2011-11-15 Biocon Limited Process for the preparation of insulin conjugate IN-105
CA2628113A1 (en) 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
EP2131855A2 (en) 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery

Also Published As

Publication number Publication date
UY33326A (es) 2011-12-01
WO2011128374A1 (en) 2011-10-20
TW201141513A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
AR080884A1 (es) Conjugados de insulina-sirna
CY1120685T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
UY31596A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
NZ595189A (en) Combination therapy with thiocolchicine derivatives
CL2013000020A1 (es) Metodo para controlar una plaga de insectos coleopteros que comprende suministrar a una plaga de coleopteros o su entorno una composicion que contiene al menos una proteina activa contra colepteros, tal como la proteina cry3a modificada activa contra lepidopteros, tal como la proteina cry1ab
BR112013027119A8 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
WO2010036918A3 (en) Intracellular dna receptor
AR083715A1 (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
CO6650337A2 (es) Derivados de 3- hidroxi-5 -arilisotiazol novedoso
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA032867B9 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
NZ595891A (en) Modulation of inflammatory responses by factor xi
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
NI201200134A (es) Polipéptidos agonistas que se enlazan a dr5
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
CL2009001240A1 (es) Compuestos derivados del acido l-glutamico y l-glutamina marcados con [f-18]; procedimiento de preparacion; composicion farmaceutica que comprende a los compuestos y su uso como agentes en el diagnostico de tumores.
BR112012014760A2 (pt) "composições orgânicas para tratar doenças relacionadas a hsf1, bem como seu uso"

Legal Events

Date Code Title Description
FB Suspension of granting procedure